Urinary levels of pro-fibrotic transglutaminase 2 (TG2) may help predict progression of chronic kidney disease

• Published in: PloS one Vol. 17; no. 1; p. e0262104
• Main Authors: Da Silva Lodge, Michelle, Pullen, Nick, Pereira, Miguel, Johnson, Timothy S
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 01.01.2022; Public Library of Science (PLoS)
• Subjects: Adult; Aged; Aged, 80 and over; Albumins; Amino acids; Analysis; Animal models; Animals; Apoptosis; Biology and Life Sciences; Biomarkers; Biomarkers - urine; Case-Control Studies; Chronic kidney failure; Clinical trials; Creatinine; Damage; Development and progression; Diabetes; Diabetes mellitus; Diabetic Nephropathies - chemically induced; Diabetic Nephropathies - metabolism; Diabetic Nephropathies - urine; Dipeptides - urine; Disease Models, Animal; Disease Progression; Enzyme-linked immunosorbent assay; Female; Fibrosis; Glomerular filtration rate; Health aspects; Histopathology; Humans; Kidney diseases; Kidneys; Lysine; Male; Measurement; Medical research; Medicine and Health Sciences; Middle Aged; Nephrectomy; Nephrectomy - adverse effects; Nephrology; Patients; Pilot Projects; Prognosis; Protein Glutamine gamma Glutamyltransferase 2 - urine; Proteins; Proteolysis; R&D; Rats; Regression Analysis; Regression models; Renal Insufficiency, Chronic - etiology; Renal Insufficiency, Chronic - metabolism; Renal Insufficiency, Chronic - urine; Research & development; Research and Analysis Methods; Sex ratio; Statistical analysis; Statistical methods; Streptozocin; Streptozocin - adverse effects; Surgery; Transglutaminase 2; Transglutaminases; Transplants & implants; Tumor necrosis factor-TNF; Urine; United Kingdom; United Kingdom > UK; United States > US
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0262104

Renal clinical chemistry only detects kidney dysfunction after considerable damage has occurred and is imperfect in predicting long term outcomes. Consequently, more sensitive markers of early damage and better predictors of progression are being urgently sought, to better support clinical decisions and support shorter clinical trials. Transglutaminase 2 (TG2) is strongly implicated in the fibrotic remodeling that drives chronic kidney disease (CKD). We hypothesized that urinary TG2 and its ε-(γ-glutamyl)-lysine crosslink product could be useful biomarkers of kidney fibrosis and progression. Animal models: a rat 4-month 5/6th subtotal nephrectomy model of CKD and a rat 8-month streptozotocin model of diabetic kidney disease had 24-hour collection of urine, made using a metabolic cage, at regular periods throughout disease development. Patients: Urine samples from patients with CKD (n = 290) and healthy volunteers (n = 33) were collected prospectively, and progression tracked for 3 years. An estimated glomerular filtration rate (eGFR) loss of 2-5 mL/min/year was considered progressive, with rapid progression defined as > 5 mL/min/year. Assays: TG2 was measured in human and rat urine samples by enzyme-linked immunosorbent assay (ELISA) and ε-(γ-glutamyl)-lysine by exhaustive proteolytic digestion and amino acid analysis. Urinary TG2 and ε-(γ-glutamyl)-lysine increased with the development of fibrosis in both animal model systems. Urinary TG2 was 41-fold higher in patients with CKD than HVs, with levels elevated 17-fold by CKD stage 2. The urinary TG2:creatinine ratio (UTCR) was 9 ng/mmol in HV compared with 114 ng/mmol in non-progressive CKD, 1244 ng/mmol in progressive CKD and 1898 ng/mmol in rapidly progressive CKD. Both urinary TG2 and ε-(γ-glutamyl)-lysine were significantly associated with speed of progression in univariate logistic regression models. In a multivariate model adjusted for urinary TG2, ε-(γ-glutamyl)-lysine, age, sex, urinary albumin:creatinine ratio (UACR), urinary protein:creatinine ratio (UPCR), and CKD stage, only TG2 remained statistically significant. Receiver operating characteristic (ROC) curve analysis determined an 86.4% accuracy of prediction of progression for UTCR compared with 73.5% for UACR. Urinary TG2 and ε-(γ-glutamyl)-lysine are increased in CKD. In this pilot investigation, UTCR was a better predictor of progression in patients with CKD than UACR. Larger studies are now warranted to fully evaluate UTCR value in predicting patient outcomes.